期刊名称：Journal of Cosmetics, Dermatological Sciences and Applications
印刷版ISSN：2161-4105
电子版ISSN：2161-4512
出版年度：2020
卷号：10
期号：2
页码：55-58
DOI：10.4236/jcdsa.2020.102006
语种：English
出版社：Scientific Research Pub
摘要：A 54-year-old man diagnosed with metastatic melanoma of the right inguinal node with occult primary developed liver and bone metastases. The combination of dabrafenib plus trametinib was initiated, and a complete response (CR) was achieved 24 months after starting treatment. One month later, the target therapy was discontinued at the patient’s decision, and he has remained free from progression for 21 months since discontinuation. To the extent of our knowledge, real-world data in Asian melanoma concerning the discontinuation of dabrafenib plus trametinib after achieving CR have not been published; therefore, our case is a meaningful one for considering to cease target drugs and to rescue their financial toxicity.
